Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma.

Giulia OrsiFrancesco TovoliVincenzo DadduzioCaterina VivaldiOronzo BrunettiLuca IelasiFabio ContiGiulia RovestiLaura GramantieriMario Domenico RizzatoIrene PecoraAntonella ArgentieroFederica TegliaSara LonardiFrancesca SalaniAlessandro GranitoVittorina ZagonelGiorgia MarisiGiuseppe CabibboFrancesco Giuseppe FoschiFrancesca BeneventoAlessandro CucchettiFabio PiscagliaStefano CascinuMario ScartozziStefano Cascinu

Published in: Targeted oncology (2021)

Our analysis identified baseline blood eosinophil counts as a new prognostic factor in patients with sorafenib-treated hepatocellular carcinoma. Concerning second-line therapies, eosinophil counts were associated with survival outcomes only in regorafenib-treated patients, suggesting a possible predictive role in this setting.

Keyphrases

prognostic factors
newly diagnosed
end stage renal disease
peripheral blood
ejection fraction
chronic kidney disease
peritoneal dialysis
metastatic colorectal cancer